NCT03647657View on ClinicalTrials.gov

177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

December 13, 2018

Primary Completion Date

December 14, 2021

Study Completion Date

December 14, 2021

Conditions
Thyroid Cancer, Medullary
Interventions
DRUG

177Lu-PP-F11N

Intravenous application of 2 x 1 gigabequerel (GBq) 177Lu-PP-F11N with and without co-medication with Sacuitril (100 mg Entresto) in each patient

DRUG

Sacuitril

Medication with Sacuitril (100 mg Entresto) additional to the injection of 177Lu-PP-F11N

Trial Locations (1)

4031

University Hospital Basel, Clinic for radiology and nuclear medicine, Basel

All Listed Sponsors
collaborator

Krebsforschung Schweiz, Bern, Switzerland

OTHER

collaborator

Center for Proton Therapy, Paul Scherrer Institute, Villigen,Switzerland

OTHER

collaborator

University Hospital, Zürich

OTHER

collaborator

University Hospital Freiburg

OTHER

lead

University Hospital, Basel, Switzerland

OTHER

NCT03647657 - 177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer | Biotech Hunter | Biotech Hunter